| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049959250 |
| P356 | DOI | 10.1007/S11596-016-1585-8 |
| P698 | PubMed publication ID | 27376797 |
| P2093 | author name string | Yong Zhang | |
| Li Liu | |||
| Wei Zhang | |||
| Yue Hu | |||
| Rui Gong | |||
| Xiao-Yan Hu | |||
| Jin-Yan Liang | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
| PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups | Q27853205 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Anti-programmed cell death protein-1/ligand-1 therapy in different cancers | Q28082259 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation | Q51888144 | ||
| Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. | Q54269172 | ||
| Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. | Q54339119 | ||
| Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. | Q55067971 | ||
| High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation | Q84014638 | ||
| Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study | Q86075907 | ||
| Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion | Q28281101 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Q29620812 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression | Q33956097 | ||
| Programmed death ligand-1 expression in non-small cell lung cancer | Q34384255 | ||
| Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis | Q34444361 | ||
| B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer | Q34459048 | ||
| PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | Q34514852 | ||
| Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy | Q34575119 | ||
| PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer | Q34778769 | ||
| B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells | Q35016870 | ||
| B7-H1 pathway and its role in the evasion of tumor immunity. | Q35117398 | ||
| PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis | Q35256558 | ||
| Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis | Q35290679 | ||
| Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation | Q35681604 | ||
| Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity | Q35762422 | ||
| A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy | Q36073248 | ||
| Immunotherapy of cancer in 2012 | Q36243536 | ||
| Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody | Q36544926 | ||
| The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures | Q37046786 | ||
| Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma | Q37708857 | ||
| Role of PD-1 in Regulating T-Cell Immunity | Q37808145 | ||
| The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. | Q38355766 | ||
| PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Q38361400 | ||
| The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis | Q38538741 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients | Q39090515 | ||
| Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. | Q39248696 | ||
| Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis | Q39308716 | ||
| B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression | Q40528021 | ||
| PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. | Q40889616 | ||
| Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status | Q41578307 | ||
| Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade | Q42020927 | ||
| T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang province | Q42254317 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 313-320 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | Journal of Huazhong University of Science and Technology. Medical Sciences | Q15711092 |
| P1476 | title | A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer | |
| P478 | volume | 36 |
| Q55440274 | Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. | cites work | P2860 |
Search more.